Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Classical approaches to immunotherapy that show promise in some malignancies have generally been disappointing when applied to high-grade brain tumors such as glioblastoma multiforme (GBM). We recently showed that ex vivo expanded/activated γδ T cells recognize NKG2D ligands expressed on malignant g...
Main Authors: | Lawrence S Lamb, Joscelyn Bowersock, Anindya Dasgupta, G Yancey Gillespie, Yun Su, Austin Johnson, H Trent Spencer |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3543433?pdf=render |
Similar Items
-
CMV-independent lysis of glioblastoma by ex vivo expanded/activated Vδ1+ γδ T cells.
by: Andrea Knight, et al.
Published: (2013-01-01) -
Characterization of Donor Variability for γδ T Cell ex vivo Expansion and Development of an Allogeneic γδ T Cell Immunotherapy
by: Rebecca E. Burnham, et al.
Published: (2020-11-01) -
γδ T Cell Immunotherapy—A Review
by: Hirohito Kobayashi, et al.
Published: (2015-02-01) -
Non-signaling Chimeric Antigen Receptors Enhance Antigen-Directed Killing by γδ T Cells in Contrast to αβ T Cells
by: Lauren C. Fleischer, et al.
Published: (2020-09-01) -
γδ T Cells: The Ideal Tool for Cancer Immunotherapy
by: Mahboubeh Yazdanifar, et al.
Published: (2020-05-01)